These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 29092957)
21. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group. Pieterman CRC; de Laat JM; Twisk JWR; van Leeuwaarde RS; de Herder WW; Dreijerink KMA; Hermus ARMM; Dekkers OM; van der Horst-Schrivers ANA; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD J Clin Endocrinol Metab; 2017 Oct; 102(10):3795-3805. PubMed ID: 28938468 [TBL] [Abstract][Full Text] [Related]
22. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter? Sallinen V; Haglund C; Seppänen H Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847 [TBL] [Abstract][Full Text] [Related]
23. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Modali SD; Parekh VI; Kebebew E; Agarwal SK Mol Endocrinol; 2015 Feb; 29(2):224-37. PubMed ID: 25565142 [TBL] [Abstract][Full Text] [Related]
24. Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors. Mohindroo C; Baydogan S; Agarwal P; Wright RD; Prakash LR; Mork ME; Klein AP; Laheru DA; Maxwell JE; Katz MHG; Dasari A; Kim MP; He J; McAllister F; De Jesus-Acosta A Cancer Prev Res (Phila); 2024 Jul; 17(7):335-342. PubMed ID: 38662083 [TBL] [Abstract][Full Text] [Related]
25. Animal models and cell lines of pancreatic neuroendocrine tumors. Babu V; Paul N; Yu R Pancreas; 2013 Aug; 42(6):912-23. PubMed ID: 23851429 [TBL] [Abstract][Full Text] [Related]
26. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240 [TBL] [Abstract][Full Text] [Related]
27. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression. Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944 [TBL] [Abstract][Full Text] [Related]
28. Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor. Williamson LM; Steel M; Grewal JK; Thibodeau ML; Zhao EY; Loree JM; Yang KC; Gorski SM; Mungall AJ; Mungall KL; Moore RA; Marra MA; Laskin J; Renouf DJ; Schaeffer DF; Jones SJM Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160355 [TBL] [Abstract][Full Text] [Related]
29. Single-cell RNA sequencing reveals spatiotemporal heterogeneity and malignant progression in pancreatic neuroendocrine tumor. Zhou Y; Liu S; Liu C; Yang J; Lin Q; Zheng S; Chen C; Zhou Q; Chen R Int J Biol Sci; 2021; 17(14):3760-3775. PubMed ID: 34671197 [No Abstract] [Full Text] [Related]
30. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms. Vandamme T; Beyens M; Boons G; Schepers A; Kamp K; Biermann K; Pauwels P; De Herder WW; Hofland LJ; Peeters M; Van Camp G; Op de Beeck K Endocr Relat Cancer; 2019 Jan; 26(1):1-12. PubMed ID: 30021865 [TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphisms of inflammatory response gene TNF-α and its influence on sporadic pancreatic neuroendocrine tumors predisposition risk. Karakaxas D; Gazouli M; Coker A; Agalianos C; Papanikolaou IS; Patapis P; Liakakos T; Dervenis C Med Oncol; 2014 Oct; 31(10):241. PubMed ID: 25213764 [TBL] [Abstract][Full Text] [Related]
32. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1. Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985 [TBL] [Abstract][Full Text] [Related]
33. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns. Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900 [TBL] [Abstract][Full Text] [Related]
34. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1. Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411 [TBL] [Abstract][Full Text] [Related]
35. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential. Camilli M; Papadimitriou K; Nogueira A; Incorvaia L; Galvano A; D'Antonio F; Ferri J; Santini D; Silvestris N; Russo A; Peeters M; Rolfo C Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):471-478. PubMed ID: 29629846 [TBL] [Abstract][Full Text] [Related]
36. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors. Chatani PD; Agarwal SK; Sadowski SM Front Endocrinol (Lausanne); 2020; 11():575620. PubMed ID: 33537001 [TBL] [Abstract][Full Text] [Related]
37. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636 [TBL] [Abstract][Full Text] [Related]
38. Prediction of lymph node metastasis in pancreatic neuroendocrine tumors by contrast enhancement characteristics. Mizumoto T; Toyama H; Terai S; Mukubou H; Yamashita H; Shirakawa S; Nanno Y; Sofue K; Kido M; Ajiki T; Fukumoto T Pancreatology; 2017; 17(6):956-961. PubMed ID: 28964660 [TBL] [Abstract][Full Text] [Related]